Novo Nordisk Says Trial of Wegovy Pill Shows Some Patients Achieve Nearly 22% Weight Loss

Published: 2026-05-13 03:17:35 ET NOVO B.CO

Published on 05/13/2026 at 03:17 am EDT - Modified on 05/13/2026 at 03:24 am EDT

By Dominic Chopping

Novo Nordisk said that almost a third of adults taking its Wegovy weight-loss pill in a trial responded early to treatment, losing an average 13.2% of their body weight after four months before going on to achieve 21.6% weight loss by the end of the 64-week trial.

The Danish drugmaker said people who were not classified as an early responder still achieved 11.5% weight loss.

The data were presented at the European Congress on Obesity in Turkey.

The once-daily Wegovy pill launched in the U.S. in early January and is expected to go on sale in other countries later this year.

Write to Dominic Chopping at [email protected]

(END) Dow Jones Newswires

05-13-26 0316ET